A common heart drug may have a secret life as a cancer fighter — and scientists now know why
The puzzle behind a heart drug's unexpected anticancer activity
Article by Dr. Safa Daoud Department of Pharmaceutical Chemistry and Pharmacognosy, Faculty of Pharmacy, Applied Science Private University, Amman, Jordan E-mail: s_daoud@asu.edu.jo
The Puzzle Behind a Heart Drug's Unexpected Anticancer Activity
Dobutamine is a well-known drug given intravenously to patients in acute heart failure, where it stimulates the heart to pump more effectively. Over the past decade, however, a growing body of research has reported something surprising: the drug also suppresses the growth of cancer cells in bone tumours (osteosarcoma), stomach cancer, and multiple myeloma. No one could fully explain why. A research team led by Dr. Safa Daoud, from the Department of Pharmaceutical Chemistry and Pharmacognosy, Faculty of Pharmacy, Applied Science Private University, Amman, Jordan, and co-led by Dr. Mutasem O. Taha from the Department of Pharmaceutical Sciences, School of Pharmacy, The University of Jordan, noticed a telling pattern in the scientific literature: all the cancers where dobutamine shows activity also tend to produce unusually high levels of a protein called ROCK2 — a molecular switch that, when left unchecked, pushes tumour cells to grow, spread, and resist treatment. The team's central question was whether dobutamine's anticancer effects could be explained, at least in part, by its ability to block ROCK2 directly.
Three Lines of Evidence, One Consistent Answer
To test this idea rigorously, the researchers used three separate approaches. First, in a laboratory enzyme assay, they measured dobutamine's ability to switch off purified ROCK2 protein. The drug blocked ROCK2 activity in a clean, dose-dependent manner, with a half-inhibitory concentration (IC50) of 7.1 µM — a finding that represents the first direct proof that dobutamine can inhibit this cancer-driving enzyme. Second, the team moved to living cancer cells. They selected two cell lines chosen specifically for their contrasting ROCK2 levels: HepG2 liver cancer cells, which produce large amounts of ROCK2, and T-47D breast cancer cells, which produce relatively little. If ROCK2 were truly dobutamine's target inside the cell, the drug should hit the first line harder. That is exactly what happened: dobutamine was 3.7 times more potent against the high-ROCK2 HepG2 cells than against the low-ROCK2 T-47D cells — a statistically significant difference that tied the drug's cancer-fighting effect directly to its target. Third, using computer modelling of the ROCK2 protein structure, the team showed precisely how dobutamine fits into the enzyme's active site, forming several stabilising molecular bonds with key residues in the region where the enzyme normally uses energy to drive cancer-cell division.
What This Means for the Future of Cancer Drug Development
The research does more than explain a long-standing mystery. It opens a practical path forward. Dobutamine has been used clinically for over 40 years, meaning its safety profile and behaviour in the human body are well understood — a significant head start compared to a brand-new compound. The study also maps out, atom by atom, where the drug's chemical structure falls short: a somewhat flexible chain and several polar groups make binding to ROCK2 less efficient than it could be. The authors propose concrete chemical modifications — such as locking the flexible chain into a ring structure and reducing unnecessary polarity — that could produce a new generation of ROCK2-blocking cancer drugs built on the dobutamine framework. While further laboratory and animal studies are needed before any clinical application can be considered, this work establishes dobutamine as a validated starting point for developing more targeted and potent ROCK2 inhibitors for cancer treatment, and adds it to a growing list of cardiovascular drugs — alongside propranolol and carvedilol — that are finding a second life in oncology.
Read the published article here: https://bit.ly/4wpKU9R
The Open Medicinal Chemistry
DOI: 10.2174/0118741045455658260423122147
If you want to publish your article please visit : https://bit.ly/4de0DRi
Journal
The Open Medicinal Chemistry Journal
Method of Research
News article
Article Title
ROCK2 Inhibition Underlying the Anticancer Effects of Dobutamine: A Novel Proposed Mechanism
No comments:
Post a Comment